The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Lisa Anson brings significant experience to the role having held a variety of senior management roles at AstraZeneca in the US and the UK. She worked in a California based healthcare company and as a management consultant with KPMG. She holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University.